ALLMedicine™ Sensory Neuropathy Center

Sep 2nd, 2021 - Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting side effect of chemotherapy. Several trials have evaluated the protective effect of vitamin E in preventing CIPN with controversial results. This study aims to outline the role o...

Aug 27th, 2021 - Although cancer and diabetes are common diseases, the relationship between diabetes, neuropathy and the risk of developing peripheral sensory neuropathy while or after receiving chemotherapy is uncertain. In this review, we highlight the effects o...

Aug 18th, 2021 - Antibodies to acetylcholine receptor (AChR) are detected in the vast majority of patients with generalized myasthenia gravis (MG) and are rarely detected in significant titer in other autoimmune diseases. We report a patient with an axonal predomi...

Aug 16th, 2021 - The severity of oxaliplatin (L-OHP)-induced peripheral sensory neuropathy (PSN) exhibits substantial interpatient variability, and some patients suffer from long-term, persisting PSN. To identify single-nucleotide polymorphisms (SNPs) predicting L...

Aug 15th, 2021 - Cerebellar ataxia, neuropathy and vestibular areflexia syndrome (CANVAS) typically presents in middle life with a combination of neuropathy, ataxia and vestibular disease, with patients reporting progressive imbalance, oscillopsia, sensory disturb...

Nov 3rd, 2010 - The aim of this guideline is to update the 2006 EFNS/PNS guideline on management of patients with a demyelinating neuropathy and a paraprotein (paraproteinemic demyelinating neuropathy [PDN]) by review of evidence and expert consensus. In the abse...

Apr 8th, 2019 - Conclusion This patient’s highly specific MRI findings, neurologic examination consistent with confusion, ataxia, length-dependent sensory neuropathy, and 360-g cumulative dose of metronidazole over the previous 6 months suggest he experienced MIE.

Feb 13th, 2019 - The Food and Drug Administration has approved a split-dosing regimen for daratumumab (Darzalex) in patients with multiple myeloma, allowing the first infusion to be split over 2 days. FDA approval is based on results from the global, multi-arm, ph.

Sep 4th, 2018 - The median progression-free survival (PFS) was not reached in the D-VMP arm and was 18. 1 months in the VMP arm.

Sep 1st, 2018 - Photo courtesy of Janssen Daratumumab (Darzalex) The European Commission (EC) has approved a new indication for daratumumab (Darzalex®). The drug is now authorized for use in combination with bortezomib, melphalan, and prednisone (VMP) to treat ad.

Jun 13th, 2018 - Rona D. Yaeger, MD Three months of adjuvant chemotherapy could be a viable option for most patients with advanced colorectal cancer (CRC), and the addition of targeted therapy should be considered for those with metastatic disease. All patients di...